Ovarian Cancer
Ovarian cancers with BRCA mutations are less immunogenic than other DNA repair–deficient tumors.
Patients with ovarian cancer can respond to immunotherapy, but rationally designed synergistic combinations will be necessary to enhance upfront efficacy and to sustain durability, said Daniel J. Powell, Jr, PhD, Scientific Director of Immunotherapy, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Using its priority review process, on March 27, 2017, the FDA approved niraparib (Zejula; Tesaro), an oral PARP inhibitor, for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors have completely or partially responded to platinum-based chemotherapy.
Frank Riessman’s Helper Theory (1965) posits that peer support networks can be powerful tools to extend care delivery—benefiting both the giver and receiver of informal care.
Endometrial and ovarian cancers are the sixth and seventh most common cancers in women worldwide.
Oral cediranib, an investigational VEGF inhibitor, in combination with a PARP or chemotherapy inhibitor, appears to have a survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data from 2 studies presented at the 2017 ASCO Annual Meeting.
Recently, a member from the Smart Patients ovarian cancer community asked, “What do you wish you knew when you were first diagnosed?” The responses ran the emotional, social, and practical gamut. We share their comments in an effort to help navigators understand the needs of newly diagnosed patients.
Compared with other cancers, ovarian cancer is relatively rare, accounting for just 1.3% of all new cancer cases in the United States.
All women with ovarian cancer should have the option of genetic testing, regardless of tumor histology, investigators in a retrospective, tissue-based analysis of a randomized trial concluded.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512